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Our understanding of the post-translational processes in-
volved in regulating the interferon regulatory factor-1 (IRF-1)
tumor suppressor protein is limited. The introduction of muta-
tions within the C-terminalMf1 domain (amino acids 301–325)
impacts on IRF-1-mediated gene repression and growth sup-
pression aswell as the rate of IRF-1degradation.However, noth-
ing is known about the proteins that interact with this region to
modulate IRF-1 function. A biochemical screen for Mf1-inter-
acting proteins has identified an LXXLL motif that is required
for binding of Hsp70 family members and cooperation with
Hsp90 to regulate IRF-1 turnover and activity. These conclu-
sions are supported by the finding that Hsp90 inhibitors sup-
press IRF-1-dependent transcription shortly after treatment,
although at later time points inhibition of Hsp90 leads to an
Hsp70-dependent depletion of nuclear IRF-1. Conversely, the
half-life of IRF-1 is increased byHsp90 in anATPase-dependent
manner leading to the accumulation of nuclear but not cytoplas-
mic IRF-1. This study begins to elucidate the role of the Mf1
domain of IRF-1 in orchestrating the recruitment of regulatory
factors that can impact on both its turnover and transcriptional
activity.
Interferon regulatory factor-1 (IRF-1),3 the founding mem-
ber of the interferon regulatory factor family, is a transcription
factor that regulates a diverse range of target genes during the
response to stimuli such as pathogen infection (1), DNA dam-
age (2, 3), and hypoxia (4). In addition, the loss of IRF-1 can
cooperate with c-Ha-ras (5) in cellular transformation; it
becomes up-regulated in cells that bear oncogenic lesions (6),
and deletions of IRF-1 are associated with the development of
gastric and esophageal tumors, as well as some leukemias (7–9).
On the basis of these observations IRF-1 has been characterized
as a tumor suppressor protein. Although initially identified as a
component of the IFN-enhanceosome complex, IRF-1 has
since been demonstrated to regulate the expression of a large
cohort of interferon-responsive genes involved in negative
growth control (10–12).
Structurally, IRF-1 includes several domains; prominent
among these is a highly conserved N-terminal sequence-spe-
cific DNA-binding domain, a transactivation domain, and a
C-terminal regulatory domain known as the enhancer (13). The
enhancer was originally identified as a region required formax-
imal IRF-1-mediated transactivation, although it does not have
intrinsic transactivation potential (13). More recent structure-
function analysis has shown that the enhancer is involved in the
recruitment of coactivators to IRF-1 target promoters (14) and
that it can facilitate IRF-1-mediated growth suppression (15), as
well as being an important determinant of the rate at which
IRF-1 is degraded (15–17). Housed within the enhancer is a
multifunctional subdomain that we have named Mf1 (Multi-
functional 1; amino acids 301–325). This domain impacts on
IRF-1-mediated transrepression of the CDK2 gene (14) and is
required formaximal IRF-1-mediated growth suppression (14).
Most recently studies have shown that Mf1 is also involved in
processing of polyubiquitinated IRF-1 by the proteasome (17).
Although the Mf1 is involved in multiple regulatory processes
(15, 17), nothing is currently known about the mechanism of
action of this region and how, for example, cellular factors
interact with the Mf1 domain to modulate IRF-1-dependent
gene expression and growth repressor activity or to promote
IRF-1 turnover.
In this study, we provide evidence linking IRF-1 to theHsp70
family and Hsp90, the core components of the molecular chap-
erone machinery. Originally defined by their role in de novo
protein folding and the response to cellular stress (18, 19), it is
now recognized that the molecular chaperones have diverse
functions in processes that include the following: protein fold-
ing (19), preventing the aggregation of denatured proteins (20),
maintenance of cell signaling and trafficking pathways (21, 22),
and the assembly and/or disassembly of multiprotein com-
plexes (23, 24). In addition, Hsp70 and Hsp90 are involved in
the regulation of diverse “client” proteins where changes in
conformation and activity of mature proteins are the primary
goal. Client proteins interact with Hsp70 and/or Hsp90 in a
cyclic manner with binding and dissociation being linked to
changes in chaperone conformation and the hydrolysis of ATP
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(25, 26). Here a requirement for the C-terminal Mf1 domain of
IRF-1 in the recruitment of Hsp70 proteins is demonstrated. In
turn it is shown that Hsp70 recruits Hsp90 and together they
have an impact on the turnover, localization, and activity of
IRF-1. The data highlight a novel IRF-1 interaction that con-
tributes to its activation pathway suggesting that the molecular
chaperones are key components of a regulatory network that
maintains IRF-1 tumor suppressor function.
MATERIALS ANDMETHODS
Chemicals, Antibodies, and Peptides—Antibodies were used
at 1g/ml and were anti-IRF-1 and anti-GFP (BD Biosciences),
anti-GAPDH (Abcam), anti-FLAG and anti-GST (Sigma), anti-
Chk1 (G-4), anti-caspase-3 (Santa Cruz Biotechnology), and
anti-Hp1 (Upstate). All antibodies to heat shock proteinswere
from StressGen. Secondary antibodies were purchased from
Dako Cytomation. 17AAG and radicicol (AG Scientific) were
dissolved inDMSOto 1mg/ml andused as detailed in the figure
legends. MG-132 (Calbiochem) was dissolved in DMSO to 10
mM and used as indicated. Cycloheximide (Supelco) was dis-
solved in water to 5mg/ml and used at 30g/ml. Peptides were
fromChironMimotopes andwere synthesizedwith a biotin tag
at the N terminus with an SGSG spacer.
Cell Culture and Transfection—A375 and H1299 cells were
cultured in Dulbecco’s modified Eagle’s medium and RPMI
1640 medium (Invitrogen), respectively, supplemented with
10% (v/v) fetal bovine serum (Autogen Bioclear) and 1% (v/v)
penicillin/streptomycin mixture (Invitrogen). Cells were
seeded 24 h before transfection. DNA (250 ng unless stated
otherwise) was transfected into the cells using Attractene (Qia-
gen) as described in the manufacturer’s instructions.
Cell Lysis and Immunoblotting—Cells were lysed in Triton
Lysis Buffer (50mMHepes, pH 7.5, 0.1% (v/v) TritonX-100, 150
mM NaCl, 10 mM NaF, 2 mM dithiothreitol, 0.1 mM EDTA, 20
g/ml leupeptin, 1 g/ml aprotinin, 2 g/ml pepstatin, 1 mM
benzamidine, 10 g/ml soybean trypsin inhibitor, 2 mM Pefab-
loc, 1.6 mM EGTA) unless otherwise indicated. 2 volume lysis
buffer was added to the cell pellet and incubated on ice for 20
min, followed by centrifugation at 16,000 g for 15min at 4 °C.
Supernatant was collected and the protein quantified by Brad-
ford assay. Samples were analyzed by SDS-PAGE and trans-
ferred to nitrocellulose (Protran, Schleicher & Schuell). The
membraneswere blocked using 5% (w/v) nonfatmilk powder in
phosphate-buffered saline  0.1% (v/v) Tween 20 (PBST) for
1 h at room temperature.Membraneswere then incubatedwith
primary antibody at 1 g/ml for 1 h at room temperature (or
overnight at 4 °C) followed by the secondary antibody (1:2000)
for 1 h. The immunoblots were washed extensively between
each step with PBST. Antibody binding was detected by
enhanced chemiluminescence.
Peptide Affinity Chromatography and Protein Identification—
A375 cell lysate (as above) was treated with avidin (Sigma) at 40
g/ml for 30min on ice and centrifuged at 16,000 g for 5min.
Treated lysates were pre-cleared using Sepharose-4B (Sigma)
beads for 1 h at 4 °C and applied to a peptide column. Peptide
affinity columns were prepared using Mobicol column jackets
(MoBiTec) containing 50l of streptavidin-agarose with biotin
peptide. Enough biotinylated peptide to saturate the streptavi-
din-agarose bead binding sites was used (Sigma) and incubated
with the beads for 1 h at room temperature, and the columnwas
then washed three times with Buffer W (100 mM Tris-HCl, pH
8.0, 150 mM NaCl, 1 mM EDTA, 1 mM benzamidine) to remove
unbound peptide. Cleared lysate (0.5 mg) was added to the col-
umn and incubated with the resin for 1 h at room temperature.
The column was washed four times with phosphate-buffered
saline 0.2%TritonX-100 and one timewith BufferW. Bound
proteins were eluted by boiling in SDS sample buffer. Eluates
were run on a 4–12% NuPAGE gel (Invitrogen), and stained
with colloidal blue (Invitrogen). Bands were excised and
trypsinized in the gel prior to analysis by one-dimensional
nanoliquid chromatography-tandem mass spectrometry using
a 4000QTrap (Applied Biosystems) tandemmass spectrometry
system (Fingerprints Proteomics Facility, University of
Dundee). The raw QTrap data were analyzed using Mascot.
Alternatively, SDS-PAGE-separated samples were transferred
onto nitrocellulose and immunoblotted as required.
Immunoprecipitation and ELISA—OneSTREP (IBA)-tagged
IRF-1 (or empty vector) was transfected into A375 cells as
described above. Post-transfection (24 h), cells were harvested
and lysed in Triton Lysis Buffer. Following this, tagged com-
plexes were purified according to the manufacturer’s instruc-
tions and analyzed by SDS-PAGE/immunoblot. For the ELISA,
purified recombinantHsp70 orHsc70 (250 ng) was coated onto
awhite 96-well plate (Fisher) in 0.1MNaHCO3buffer, pH8.6, at
4 °C. Nonreactive sites were blocked using phosphate-buffered
saline containing 3% bovine serum albumin. Empirically deter-
mined amounts of the protein of interest (GST, GST-IRF-1
WT, or GST-IRF-1 Enh) were added in 1 Reaction Buffer
(25 mM Hepes, pH 7.5, 50 mM KCl, 10 mM MgCl2, 5% (v/v)
glycerol, 0.1% (v/v) Tween 20, 2 mg/ml bovine serum albumin)
for 1 h at room temperature. After washing extensively in phos-
phate-buffered saline containing 0.1% (v/v) Tween 20, binding
was detected using anti-GST and horseradish peroxidase-
tagged anti-mouse antibodies, and electrochemical lumines-
cence was quantified using a luminometer (Labsystems; Fluo-
roskan Ascent FL).
Size Exclusion Chromatography—A375 cells were lysed in
fast protein liquid chromatography Lysis Buffer (20 mMHepes,
pH 7.5, 0.25 MNaCl, 10% (w/v) sucrose, 10% (v/v) glycerol, 0.1%
(v/v) Triton X-100, 5mMNaF, 2mM-glycerophosphate, 1mM
dithiothreitol, 20 g/ml leupeptin, 1 g/ml aprotinin, 2 g/ml
pepstatin, 1 mM benzamidine, 10 g/ml soybean trypsin inhib-
itor, 2 mM Pefabloc, 1.6 mM EGTA) and passed through a
0.45-m filter. Lysate generated from 1  10-cm plate
extracted in 500 l of buffer was loaded onto a 25-ml Super-
ose-6 column (AmershamBiosciences) equilibrated in fast pro-
tein liquid chromatography column buffer (20 mM Hepes, pH
7.5, 0.25MNaCl, 5% (w/v) sucrose, 5% (v/v) glycerol, 0.05% (v/v)
Triton X-100, 5 mM NaF, 1 mM dithiothreitol, 1 mM benzami-
dine). The flow rate was adjusted to 0.4 ml/min, and 0.5-ml
fractions were collected. Fractions were precipitated using tri-
chloroacetic acid and analyzed by SDS-PAGE/immunoblot.
mRNA Extraction and RT-PCR—H1299 cells were treated
with 17AAG as indicated and harvested. Half of the cells were
lysed in Triton Lysis Buffer, and analyzed for protein. From the
remaining 50% of cells, RNA was extracted using the RNeasy
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mini kit (Qiagen). The extracted RNA was reverse-transcribed
using the Omniscript RT kit (Qiagen). PCR was performed
using PCRMaster Mix (VH Bio) and an annealing temperature
of 55 °C for 25 cycles. Primer sequences were as follows: IRF-1,
TTAATAAAGAGGAGATGATCTTCC/CCTGCTTTGTA-
TCGGCCTGTGTGA and GAPDH, GTCAGTGGTGGACC-
TGACCT/ACCTGGTGCTCAGTGTAGCC.
Luciferase Assay—For luciferase reporter assays, cells were
cultured in 24-well plates and transfected with pCMV-Renilla/
Luc (60 ng) together with either TLR3-Firefly/Luc WT or
mutant (ISRE; 140 ng). Luciferase assayswere performed 24 h
post-transfection using theDual Luciferase reporter assay sys-
tem (Promega) according to the manufacturer’s instructions.
Luminescence was quantified using a Fluoroskan Ascent F1
luminometer (Labsystems). Signals were normalized using the
internal control (Renilla luciferase signal). Results are repre-
sented as mean S.D.
Subcellular Fractionation and Half-life Analysis—Subcellu-
lar fractionation was carried out using the ProteoExtract kit
(Calbiochem) according to the manufacturer’s instructions.
For the half-life determination, A375 cells in 35-mm plates
were transfected as indicated in the figure legends. Post-trans-
fection (24 h), the cells were treated with 30 g/ml cyclohexi-
mide and harvested at the indicated time points. Samples were
fractionated as described above. Nuclear fractions (40g) were
analyzed by SDS-PAGE/immunoblot. Band intensitywas quan-
tified using Scion Imaging software. The intensity of the zero
time point was taken as 100%, and the others were measured
relative to this. A graph of ln(% protein remaining) against time
was plotted to obtain a linear graph. The equation of the graph
was used to calculate the x axis value corresponding to y 
ln(50%). This value represents the calculated half-life.
RESULTS
Identification of the Molecular Chaperone Hsp70 as a Novel
IRF-1-binding Protein—The C-terminal enhancer region of
IRF-1 (Fig. 1A) is an important regulatory domain (14–16). Of
particular interest is theMf1 region (amino acids 301–325) that
is essential for maximal IRF-1-mediated growth suppression
(15) and that plays a key role in determining the rate of IRF-1
degradation (17). In a quest to identify factors that mediate the
regulatory functions of theMf1 domain,we adapted a biochem-
ical screen (Fig. 1B) developed to identify protein interaction
motifs in IRF-1.4 A biotin-labeled peptide (pep-(301–320))
based on amino acids 301–320 of IRF-1 was immobilized using
streptavidin-agarose and used to generate an affinity column
(50-l volume). The column was loaded with A375 cell extract
andwashed extensively prior to the recovery of bound proteins.
Eluted protein was analyzed using SDS-PAGE on 4–12% gra-
dient gels and individual bands identified by mass fingerprint-
ing (Fig. 1C, left panel). The major protein band pulled out by
the pep-(301–320) column (Fig. 1C, left panel arrow) was ana-
lyzed by mass fingerprinting and was found to contain both
constitutive and inducible members of the Hsp70 family of
molecular chaperones. Immunoblot analysis using an Hsp70-
specific antibody was used to confirm the mass fingerprint
identification (Fig. 1C, right panel).
Hsp70 Binds Directly to IRF-1—The data presented above
suggest thatHsp70 familymembers can bind to a 20-amino acid
peptide based on part of the Mf1 domain. Based on this obser-
vation, evidence was sought that Hsp70 could bind the Mf1
region of IRF-1 when found in the context of the full-length
protein. First, size exclusion chromatography was used to
determinewhether cellular IRF-1 andHsp70 coeluted in aman-
ner consistent with complex formation in the cellular environ-
ment. Using a Superose-6 column, IRF-1 from A375 cell lysate
was found to elute in three distinct peaks (Fig. 2A) as follows:4 V. Narayan and K. L. Ball, unpublished data.
FIGURE 1. Identification of the molecular chaperone Hsp70 as an IRF-1-
interacting protein. A, IRF-1 domain organization. NLS, nuclear localization
signal; Mf1, multifunctional domain 1. B, overview of the method used to
identify the C-terminal IRF-1-interacting proteins.C, eluates from themethod
depicted inBwere runon4–12%gradientgels and stainedwith colloidal blue
(left panel). Right panel, duplicate gel was run and transferred to nitrocellu-
lose. The immunoblot was developed using the Hsp70mAb (clone SPA-810).
In addition to IRF-1 peptide 301–320, a p21 peptide (amino acids 15–34) and
a second IRF-1 peptide (amino acids 196–215)were used as controls to check
for nonspecific binding.
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one in the void volume (peak 1) and two that were included
(peaks 2 and 3), indicative of multiple IRF-1-containing com-
plexes. Peak 2 coeluted with fractions that also contained
Hsp70 suggesting that cellular
IRF-1 and Hsp70 may be present in
the same complex. To provide fur-
ther evidence of Hsp70-IRF-1 com-
plex formation in cells, OneStrep-
tagged IRF-1 was expressed in A375
cells and captured using a Streptac-
tin column. Fig. 2B shows that
OneStrep-IRF-1 was quantitatively
depleted from cell extracts by Strep-
tactin with no tagged-IRF-1 detect-
able in the flow-through. When
OneStrep-IRF-1 bound protein was
analyzed for the presence of 70-kDa
heat shock protein family members
using an antibody toHsp/c70, of the
three isoforms detected in the cell
extract, only one isoform bound
specifically to IRF-1 (Fig. 2B), and
no binding was detected in the con-
trol lane. This suggests that the
interaction between full-length IRF-
1 and the cellular Hsp70 proteins is
fairly specific as one isoform bound
with a higher affinity.
The above experiments suggest
that Hsp70 family members can
form a complex with IRF-1 in cells
and that the interaction is specific to
certain Hsp70 isoforms; however,
they do not address whether the
interaction is direct or if additional
cellular factors are required. To
determine whether Hsp70 could
bind directly to IRF-1, we used
recombinant proteins purified from
E. coli. Hsp70 andHsc70 (27) bound
to GST-IRF-1 when they were
immobilized (Fig. 2C). However, the
affinity of Hsp70 was an order of
magnitude greater than that of
Hsc70 suggesting that IRF-1 inter-
acts preferentially with Hsp70.
As the interaction between IRF-1
and Hsp70 was identified using an
Mf1 domain peptide (pep-(301–
320); Fig. 1C), we determined
whether the C-terminal domain
was required for Hsp70 to bind full-
length IRF-1. To do this a C-termi-
nal IRF-1 deletion mutant (IRF-
1Enh (15) was purified from an
E. coli expression system. A com-
parison ofHsp70 binding to purified
WT and Enh IRF-1 (Fig. 2D) sug-
gests that deletion of the C-terminal Mf1 domain leads to a
significant decrease in the affinity of IRF-1 for Hsp70 support-
ing a role for the enhancer domain in engaging the chaperone
FIGURE 2. Hsp70 interacts with IRF-1 in vitro and in cells. A, lysate from A375 cells stably expressing IRF-1 was
analyzedbysizeexclusionchromatography.Protein fromeach fraction (0.5ml)wasprecipitatedusing trichloroace-
tic acidandanalyzedby12%SDS-PAGE/immunoblotdevelopedusing IRF-1mAbandanti-Hsp/c70.B, immunoblot
(IB) of OneStrep-IRF-1 isolated using Streptactin from A375 cells that had been transiently transfected with
OneStrep-IRF-1oremptyvectoras indicated.Theimmunoblotswereprobedfor IRF-1andHsp/c70(SPA-822).Crude
cell extract (CE) and flow-through (FT) from theStreptactin columnare shown, andC is abeadonly control. Inserted
is a schematic of the gel showing that although there are three Hsp/c70 isoforms picked up by the antibody, only
oneof thesecomesdownwith IRF-1.Co-IP, coimmunoprecipitation.C, recombinantHsp70andHsc70purified from
E. coli (50ng)were coatedontoamicrotiterplate and incubatedwitha titration (0–25ng)ofGST-IRF-1. Bindingwas
detected using an anti-GST antibody and enhanced chemiluminescence. Protein concentration against binding,
expressedas relative lightunits (RLU), is shown.The results are representativeof threeseparateexperiments.D, as in
C, Hsp70was coatedonto an ELISAplate and incubatedwith a titration (0–50ng) ofGST, GST-IRF-1WT, orGST-IRF-
1enh. Protein concentration against binding, expressed as relative light units (RLU), is shown. The results are
representative of four separate experiments. E, panel of overlapping IRF-1 peptides spanning the entire length of
theproteinwasusedtogenerateaffinitycolumns (seeFig.1B) todeterminewhetherHsp70fromA375 lysatebound
to sites on IRF-1 other than the Mf1 domain. Bound proteins, including Hsp70, were eluted in sample buffer and
analyzed by SDS-PAGE/immunoblot using anti-Hsp70 mAb (SPA-810). The results are representative of two inde-
pendent experiments.
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machinery. In addition, as residual Hsp70 binding to the Enh
IRF-1 protein was detected, the interaction between IRF-1 and
Hsp70 is likely to be complex, involving more than one inter-
face. To confirm the presence of an additional interface(s) for
Hsp70 in IRF-1, we used a series of overlapping peptides that
spanned the length of IRF-1 and asked if any of these peptides
could bind to Hsp70 from cell lysates. Fig. 2E shows that Hsp70
bound predominantly to the Mf1 domain and to a second pep-
tide based on a region from the N-terminal DNA binding
domain of IRF-1 (amino acids 91–110). As the crystal structure
for the N-terminal domain of IRF-1 has been solved (28), we
were able to see that this region of IRF-1 forms a solvent-ex-
posed flexible loop (data not shown). Thus, IRF-1-Hsp70 com-
plex formation appears to require at least two distinct inter-
faces, one of which is composed of a solvent-exposed flexible
loop.
Inhibition of Hsp90 Decreases IRF-1 Protein Levels—Hsp70,
together with a second molecular chaperone Hsp90, is an
essential component of a multiprotein complex that interacts
with key regulatory factors involved in the control of cellular
proliferation, differentiation, and death. Although Hsp90 has
been demonstrated to interact directly with some client pro-
teins in vitro, there is speculation that in the cellular environ-
ment Hsp90 will inevitably function together with Hsp70 (25,
29). As the results presented above suggested that IRF-1 can
interact specifically with Hsp70 both in vitro and in a cellular
environment, we sought to determine whether IRF-1 was also a
client of the Hsp90 chaperone complex. Hsp90 client proteins
are targeted for proteasomal degradation upon treatment with
Hsp90-specific inhibitors such as
17AAG and radicicol (30, 31).
When A375 cells were treated with
a titration of 17AAG (25 nM to 20
M), IRF-1 protein steady state lev-
els decreased by 12 h using concen-
trations of the drug in the low nano-
molar range (Fig. 3A, compare lanes
3 and 4 with lane 1). The effect of
17AAG on IRF-1 was verified in a
second cell line as IRF-1 steady state
levels were reduced by the drug in
H1299 cells, as well as in A375 cells
(Fig. 3B).
To confirm that the 17AAG-in-
duced decrease in the steady state
levels of the IRF-1 protein was
because of Hsp90 inhibition, and
not an off-target effect of the drug
itself, a second Hsp90 inhibitor,
radicicol, was used. Although the
mechanism of action of radicicol
and 17AAG are similar (both bind
to and block the ATP-binding site
on Hsp90), radicicol is structurally
unrelated to 17AAG. Fig. 3C (com-
pare lanes 2 and 3 to lane 1) dem-
onstrates that, similar to 17AAG,
radicicol treatment causes a de-
crease in IRF-1 protein levels.
Effect of 17AAG on IRF-1 Is Post-translational—To deter-
mine at which stage in the IRF-1 regulatory pathwayHsp90was
operating, we first asked whether 17AAG was able to act on
exogenous as well as endogenous IRF-1. Fig. 4A shows that
IRF-1 proteins expressed in an untagged form (lanes 3 and 4)
and as a FLAG fusion protein (lanes 5 and 6), like endogenous
IRF-1 (lanes 1 and 2), were sensitive to treatment with 17AAG,
suggesting that the drug was not functioning through an effect
on the IRF-1 promoter. This conclusion was supported by data
showing that 17AAG used at either 1 or 10 M had no effect on
IRF-1 mRNA levels (Fig. 4B). As Hsp90 inhibitors have been
shown to stimulate degradation of client proteins via the
ubiquitin-mediated proteasome pathway, we tested whether
17AAG-dependent IRF-1 loss was sensitive to the proteasome
inhibitor MG132. As shown in Fig. 4C, the effect of 17AAG on
IRF-1 protein levels was partially lost upon treatment with
MG132 (compare lanes 1 and 3 with lane 4), suggesting that
proteasome-dependent degradation may play a role in the
decrease in IRF-1 steady state levels observed upon inhibition
of Hsp90 and that the effect of 17AAG is post-translational.
Hsp90 Inhibition Modulates IRF-1 Transcriptional Activity—
Treatment of cells with 17AAG led to a decrease in IRF-1 pro-
tein levels at 12 h post-treatment; however, at earlier time
points the steady state levels of IRF-1 were not affected signifi-
cantly by Hsp90 inhibition (Fig. 5A). The time-dependent
nature of 17AAGwas exploited to assess its effect on the ability
of endogenous IRF-1 to activate transcription at time points
where no change in total IRF-1 protein levels was seen. Using a
FIGURE 3. Hsp90 inhibition induces a decrease in IRF-1 protein levels. A, A375 cells were treated with the
indicated concentrations of 17AAG for 12 h. Cells were lysed and analyzed by SDS-PAGE/immunoblot devel-
oped using IRF-1 mAb and anti-GAPDH. The experiment is representative of at least two individual experi-
ments.B,A375andH1299 cellswere treatedwith17AAGor theDMSOcarrier as indicated for 20h. Lysateswere
analyzed as above and are representative of two separate experiments. C, A375 cells (untransfected or trans-
fected with FLAG-IRF-1) were treated with the indicated concentrations of radicicol for 20 h. Lysates were
analyzed by SDS-PAGE/immunoblot, and probed for IRF-1 and GAPDH as above.
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reporter inwhich theTLR3promoter, an IRF-1 target gene (32),
was linked to the expression of luciferase, 17AAG (1 M) treat-
ment consistently caused a decrease in IRF-1 activity prior to
decreases in IRF-1 steady state levels (Fig. 5B). As IRF-1 is
described as a relatively weak transcriptional activator (13),
even small changes in its activity are likely to have a significant
impact on its biological function. Fig. 5C shows that the 17AAG
effect was specific for IRF-1 as a TLR3 control plasmid minus
the IRF-1 consensus site was not activated in A375 cells.
Inhibition of Hsp90 by 17AAG therefore has a bi-phasic
effect on IRF-1; in the early signaling phase, IRF-1 activity as a
transcriptional activator is inhibited, and in a second phase,
IRF-1 protein levels are down-regulated through a post-trans-
lational pathway that can be blocked by proteasome inhibition.
Hsp90 Regulates IRF-1 Turnover and Nuclear Accumulation—
The degradation of IRF-1 upon inhibition of Hsp90 suggests
that it is an Hsp70/Hsp90 client protein. To determine the nor-
mal role of the chaperone system in the pathways leading to
regulation of IRF-1, A375 cells were transiently transfected
with FLAG-Hsp90. Both the - and -isoforms of Hsp90 pro-
duced an increase in the amount of
endogenous IRF-1 protein detected
(Fig. 6A). Furthermore, Hsp90-me-
diated increases in IRF-1 were
dependent on its ATPase activity
(Fig. 6B). Thus, an Hsp90 mutant
that could bind to but not hydrolyze
ATP (Fig. 6B, lanes 4–6, E46A) had
no effect on IRF-1 protein levels
under conditions where WT Hsp90
increases the levels of IRF-1 (lanes
1–3). In addition, a dominant nega-
tive form of Hsp90 (Fig. 6B, lanes
7–9, D93N), which is incapable of
binding ATP, has a similar effect to
17AAG, producing a decrease in
IRF-1 protein levels.
IRF-1 is normally distributed bet-
ween the cytoplasmic and the nuclear
compartments of the cell, with a sub-
stantial proportion in the nucleus.
Cellular fractionation studies were
therefore employed to determine
whether Hsp90 affected the balance
between these two pools. Fig. 6C
shows that Hsp90 preferentially
increases the pool of nuclear IRF-1,
with no increase detected in the
cytoplasmic fraction (compare lane
3 with lane 1). Conversely, inhibi-
tion of Hsp90 by 17AAG caused a
preferential loss of protein from the
nuclear pool when compared with
the cytoplasmic pool (Fig. 6D, com-
pare lanes 3 and 7 with lanes 1 and
5). When the half-life of IRF-1 was
determined (Fig. 6E) in the nuclear
fraction of cells overexpressing
either Hsp90 or Hsp90, a decrease in the rate of IRF-1 deg-
radation with the half-life going from 40 min in control cells to
60min in the presence of overexpressedHsp90 was seen (Fig.
6E, lower panel).
The results presented in this section support a model where
Hsp90 favors the accumulation of nuclear IRF-1 through
increases in steady state levels resulting from a decrease in the
rate of IRF-1 degradation.However, we cannot exclude the pos-
sibility that Hsp90 might also be involved in transport of IRF-1
into the nucleus as has been demonstrated for p53 (33).
Hsp90 Regulation of IRF-1 Is Mediated by Hsp70 Binding—
The discovery of Hsp70 as a C-terminal IRF-1-binding protein
led us to identify Hsp90 as a key regulator of IRF-1 in the cellu-
lar environment. To address whether the regulation of IRF-1 by
Hsp90 is mediated through Hsp70, and particularly through
binding of Hsp70 to the enhancer domain of IRF-1, we first
determined the effect of dominant negative Hsp70 (Fig. 7A,
K71S, lanes 5 and 6) on the ability of 17AAG tomodulate IRF-1
steady state levels. Expression of the Hsp70/K71S mutant by
itself led to a reduction of IRF-1 steady state levels when com-
FIGURE 4. 17AAG-dependent loss of IRF-1 is post-translational. A, A375 cells were transiently transfected
with pcDNA3-IRF-1 (IRF-1 wt), FLAG-IRF-1, or empty vector as indicated and treated with 17AAG (1 M) 24 h
later. Lysates were analyzed by SDS-PAGE/immunoblot developed using IRF-1 mAb and anti-GAPDH. Lanes 1
and 2were loadedwith 75gof total protein so that endogenous IRF-1 could be detected, whereas 25gwas
loaded into the other lanes to detect the transfected protein. The data are representative of at least two
separate experiments. B, H1299 cells were treated with the indicated concentrations of 17AAG and harvested
at various times post-treatment. Half of the cells were used to analyze IRF-1 and GAPDH protein levels by
SDS-PAGE/immunoblot, and the remainderof the cellswereused tomeasure IRF-1 andGAPDHmRNA levels by
RT-PCR. The data are representative of two experiments. C, A375 cells were treatedwith 17AAG (1M) for 12 h
prior to the addition of MG132 for a further 4 h. Lysates were analyzed as above and are representative of two
separate experiments.
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paredwith control cells and to cells transfectedwithWTHsp70
(Fig. 7A, compare lane 5 with lane 1). In addition, in the pres-
ence of the K71S Hsp70 mutant protein, 17AAG was unable to
further reduce the levels of IRF-1 under conditions where levels
were significantly decreased in control cells. Next we asked
whether the down-regulation of IRF-1 steady state levels in
17AAG-treated cells required its Mf1 domain by using an
enhancer domain deletion mutant. Under conditions where
17AAG decreased the expression of both endogenous and
transfected WT IRF-1 protein, it had no effect on an IRF-1
mutant protein from which the
enhancer domain had been deleted
(Fig. 7B, lanes 5 and 6). In fact the
levels of the IRF-1Enh mutant
increased rather than decreased in
17AAG-treated H1299 cells (IRF-
1enh low exp), suggesting that this
protein is resistant to Hsp70-medi-
ated degradation. As a control we
determined that the levels of the
known Hsp90 clients Chk1 and p53
decrease in response to 17AAG in
the same samples where IRF-1enh
protein was seen to increase (Fig.
7B, compare lanes 5 and 6).
Fine mapping of the interaction
betweenHsp70 and theMf1domain
peptide of IRF-1 was carried out to
identify critical contact residues
that could then be manipulated to
make more specific IRF-1 Hsp70-
binding mutants. A library of IRF-1
pep-(301–320) peptides was syn-
thesized in which each amino acid
was sequentially replaced with an
alanine residue, and the pep-(301–
320) library was used to generate a
series of affinity columns. Cell lysate
was loaded onto the columns, and
following extensivewashing the col-
umns were eluted, and bound pro-
tein was analyzed by immunoblot to
identify peptides that showed re-
duced binding to cellular Hsp70.
Using this approach we found that
Hsp70 bound to a discrete interac-
tion motif that included a coregula-
tor signature (LXXLL) motif and a
number of proline residues (Fig.
7C). Using the information obtained
by fine mapping the Hsp70 interac-
tionwith theMf1 domain of IRF-1, a
mutant construct was used where
alanine residues had been intro-
duced into the LXXLL motif (15).
When the effect of radicicol on
wild-type and LXXLL mutant IRF-1
was compared, the levels of endog-
enously and exogenously expressed wild-type IRF-1
decreased following radicicol treatment (Fig. 7D, compare
lanes 2 and 4 with 1 and 3) while those of the LXXLL mutant
protein did not decrease, but similar to Enh IRF-1 (Fig. 7B),
the amount of protein was increased by Hsp90 inhibition
(Fig. 7D, lanes 5 and 6). The data presented in this section
lend support to the hypothesis that Hsp70 binding to an
interaction motif within the Mf1 domain of IRF-1 mediates
Hsp90-dependent modulation of IRF-1 steady state levels in
the nucleus.
FIGURE 5.Hsp90 inhibition affects IRF-1 transcriptional activity. A, A375 cells were treated with 17AAG
(1 M) for the indicated times. Lysates were analyzed by SDS-PAGE/immunoblot developed using IRF-1
mAb and anti-GAPDH. C is DMSO-treated control cells, and the results are representative of at least three
individual experiments. B, H1299 cells were cotransfected with a TLR3-fireflyLUC reporter plasmid (140
ng), and control Renilla-LUC (60 ng). Post-transfection (24 h), the cells were treated with 17AAG (1M) and
harvested at the indicated times. Dual luciferase assays were performed, and the results were normalized
by expressing TLR3-fireflyLUC/Renilla activity in relative light units (RLU) as the mean  S.D. C, as above
except that a control TLR3 plasmid (TLR3 mutant) lacking the interferon-stimulated response element is
included.
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DISCUSSION
Despite the fact that IRF-1 is involved in cellular processes
ranging from the antiviral response to tumor suppression,
only a handful of IRF-1-interact-
ing proteins has been identified.
Structure-function analysis has
defined the enhancer domain as a
key regulatory site involved in con-
trolling IRF-1-dependent effects on
gene expression and cell growth.
Furthermore, we have defined the
Mf1 domain as a distinct region of
the enhancer that contains an
LXXLL motif that is central to both
IRF-1-mediated repression of Cdk2
(15) and the degradation of polyu-
biquitinated IRF-1 (17). To define
components of the IRF-1 interac-
tome whose binding to the Mf1
domain has functional conse-
quences, we set up a biochemical
screen for proteins that bind to
amino acids 301–320 of IRF-1.
Hsp70 was delineated as an LXXLL
motif-binding protein, and the Mf1
domain was shown to mediate
Hsp70/Hsp90-dependent modula-
tion of IRF-1 turnover, activity, and
localization.
Studies carried out on the
enhancer domain have implicated
theMf1domain inmultifaceted reg-
ulation of IRF-1 transcription factor
activity and growth suppressor
function (15, 17). Thus, deletion of
the C-terminal 25 residues impairs
the ability of IRF-1 to suppress cell
growth in a colony formation assay
and also leads to a loss of its Cdk2
repressor function (12, 15). An
LXXLL motif embedded within this
region appears to be critical for the
role of this domain in controlling
both IRF-1 biological activity (15)
and in determining how IRF-1 is
regulated by the ubiquitin protea-
some system (17). In this study we
have identified proteins that bind to
the Mf1 region of IRF-1, prominent
among these being members of the
molecular chaperone Hsp70 fami-
ly. Interestingly, although several
Hsp70/Hsc70 isoforms are detected
in A375 cells (Fig. 2B), only one is
pulled down efficiently with IRF-1
suggesting that the interaction is
specific. In addition, in vitro binding
assays showed that Hsp70 binding
to IRF-1 was an order of magnitude better than Hsc70 binding,
although we cannot rule out a role for Hsc70 in vivo. Fine map-
ping of the interaction between Hsp70 and the C terminus of
FIGURE 6. Hsp90 causes IRF-1 nuclear accumulation. A, A375 cells were transiently transfected with a titra-
tion (0–10 g) of FLAG-Hsp90 or - for 24 h with DNA levels normalized using empty vector. Lysates were
analyzed by SDS-PAGE/immunoblot developed using IRF-1 mAb, anti-FLAG, and anti-GAPDH antibodies. The
data are representative of at least three separate experiments, and c is amock-transfected control. B, A375 cells
were transiently transfected with increasing amounts of YFP-Hsp90 (WT or ATP mutants E46A and D93N; 0–5
g) and analyzed as in A. The results are representative of two separate experiments. C, A375 cells were
transiently transfected with FLAG-Hsp90 or - or empty vector (5 g), and 24 h post-transfection the cells
were harvested and fractionated using a ProteoExtract kit. The fractions were analyzed by SDS-PAGE/immu-
noblot developed using IRF-1 mAb, anti-caspase-3, and anti-Hp1 antibodies. D, A375 cells were transiently
transfected with WT IRF-1 or left untransfected and subsequently treated with 17AAG (1 M). After 24 h cells
were harvested, fractionated, and analyzed as in C. Caspase 3 andHp1were used asmarkers for the cytoplas-
mic andnuclear fractions, respectively. E,A375 cellswere transiently transfectedwith a constant amount (5g)
of FLAG-Hsp90 or - or empty vector, and 24 h post-transfection, the cells were treated with cycloheximide
(30 g/ml) for the indicated times. Cells were harvested and fractionated as in C. The nuclear fraction was
analyzed by SDS-PAGE/immunoblot and developed using IRF-1 mAb or anti-FLAG antibody. To calculate the
half-life, band intensitywas quantified using Scion Imaging software, and ln(%protein remaining)was plotted
against time to obtain a linear graph.
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FIGURE 7. Hsp70-binding motif within the C terminus mediates Hsp70:Hsp90 dependent effects on IRF-1. A, H1299 cells were transiently transfected with
YFP-Hsp70 (WTor thedominant negativemutant K71S; 250ng) or empty vector; 24 h later 17AAG (1M)was added and the incubation continued for a further 20 h.
LysateswereanalyzedbySDS-PAGE/immunoblotdevelopedusing IRF-1mAb,anti-Hsp70,andanti-GAPDHantibodies.B,A375cellswere transiently transfectedwith
pcDNA3-IRF-1WTorenhoremptyvectorandthentreatedwith17AAG(1M)andanalyzedasabove.The levelsofChk1,Hsp70,andp53weremeasuredascontrols.
The data are representative of two separate experiments. C, alanine substitutions were introduced into the C-terminal IRF-1 peptide (pep-(301–320)) so that each
aminoacidwassequentiallymutated(lowerpanel) andusedtogenerateaseriesofaffinitycolumns.Followingthe isolationofpeptide-bindingproteins fromA375cell
lysate, thecolumnswereeluted,andtheeluatewasanalyzedbySDS-PAGE/immunoblotdevelopedusinganti-Hsp70mAb(SPA-810).AconsensusbindingsiteforHsp70
in IRF-1 is shown.D,A375cellswere transiently transfectedwith IRF-1WToranLXXLLmutant, and thecellswere then treatedwith radicicol (10M)andanalyzedas inB.
Cooperative Regulation of the IRF-1 Tumor Suppressor Protein
SEPTEMBER 18, 2009•VOLUME 284•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 25897
 at Edinburgh University Library on August 26, 2013http://www.jbc.org/Downloaded from 
IRF-1 demonstrated that the LXXLL motif, along with several
proline residues, was an essential component of the interaction.
Previous studies have shown that the E. coliHsp70 homologue
DnaKbinds preferentially to regionswith a hydrophobic core of
4–5 amino acids, particularly where these are enriched in
leucine residues (34, 35). Interestingly, however, although pre-
vious studies using DnaK or recombinant Hsp70 showed a rel-
atively “loose” specificity for Hsp70 binding, in the current
study using endogenous Hsp70 from human cells, mutation of
specific Leu or Pro residues showed complete loss of Hsp70
binding even though the environment was predominantly
hydrophobic. It is interesting to speculate that the difference
may reflect post-translational regulation ofHsp70 and its inter-
actions by, for example, cochaperones (21) or post-transla-
tional modifications, such as the recently describedmonoubiq-
uitination of Hsp70 (36).
In this study Hsp90 was able to modulate both IRF-1 turn-
over and its activity as a transcription factor. In response to
17AAG, in common with other Hsp90 client proteins (37),
IRF-1was targeted for degradation. A requirement forHsp70 in
the 17AAG-activated degradation pathway was demonstrated
using a dominant negative Hsp70 construct and by the use of
IRF-1 mutant proteins where the C-terminal Hsp70-binding
site in the Mf1 domain had been deleted or mutated. Thus
degradation of IRF-1 in 17AAG-treated cells most likely
involves an Hsp70-associated ubiquitin-protein isopeptide
ligase such as CHIP or Parkin (38, 39). Interestingly, prior to the
effect of 17AAG on IRF-1 levels, there was a decrease in its
transcriptional activity, suggesting that inhibition of Hsp90 has
a biphasic effect on IRF-1. At early time points, inhibition of
Hsp90 ATPase activity decreases IRF-1 transcriptional activity
and is uncoupled from the changes in IRF-1 protein levels that
occur at later time points. It will therefore be of interest to
determine precisely how blocking the ATPase function of
Hsp90 affects IRF-1 conformation and whether this impacts,
for example, on the ability of IRF-1 to bind DNA or assemble
into a preinitiation complex (see below). The conclusion we
have drawn from this is that Hsp90 normally acts as a positive
regulator of IRF-1. Supporting this is the observation that over-
expression of Hsp90 leads to an increase in the half-life of IRF-1
within the nucleus. Interestingly, the use of dominant negative
Hsp70, by itself, was sufficient to reduce the levels of endoge-
nous IRF-1. As the K71S mutant form of Hsp70 is impaired in
its ability to fold substrates (40), the data also implicate Hsp70,
either by itself or in cooperation with Hsp90, as a positive reg-
ulator of IRF-1.
The classic view of the molecular chaperones is that they are
primarily involved in the folding of nascent proteins and the
prevention of protein aggregation. More recently, the core
molecular chaperone machinery, including Hsp70 and Hsp90,
has been suggested to take primary responsibility for maintain-
ing a dynamic cellular environment (23, 41) by taking part in
transient low affinity protein-protein interactions (25). In addi-
tion some members of this group, most notably Hsp90, have
more selective roles binding preferentially to specific classes of
already folded proteins (42). Large scale screens for novel phys-
ical and genetic interactions with Hsp90 in yeast have recently
revealed that it interacts with a much greater range of proteins
than previously thought. Of particular interest with respect to
IRF-1 is the light that these and other studies cast on the role of
the chaperones in regulating gene expression (43–45). To-
gether with evidence that Hsp70 can control gene expression
throughmodulation of transcription factor structure and func-
tion, these studies also suggest several possible mechanisms by
which Hsp70 and/or Hsp90 could affect IRF-1 transactivation.
These include the following: control of transcription complex
assembly and/or disassembly (24, 46); modulation of sequence-
specific DNA binding (27, 47, 48); access to promoter elements
within chromosomal DNA (44, 49); or assisting in the post-
translational modification of IRF-1 as has been demonstrated
for the related transcription factor IRF-3 (50).
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